1 unchanged sentence
Unregistered Sales of Equity Securities
−Removed: We did not sell or issue any equity securities during the three months ended March 31, 2020 that were not registered under the Securities Act of 1933, as amended, or the Securities Act.
−Removed: Use of Proceeds from Registered Securities
+Added: We did not sell or issue any equity securities during the three months ended June 30, 2020 that were not registered under the Securities Act of 1933, as amended, or the Securities Act.
+Added: Use of Proceeds from Initial Public Offering of Common Stock
On May 9, 2019, we closed our initial public offering, or IPO, in which we issued and sold 5,500,000 shares of common stock at a public offering price of $10.00 per share.
−Removed: The aggregate gross proceeds to us from our IPO offering were $55.0 million.
+Added: The aggregate gross proceeds to us from our IPO were $55.0 million.
All of the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No.
2 unchanged sentences
No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.
−Removed: As of March 31, 2020, we had not used any of the net proceeds from the IPO.
−Removed: There has been no material change in our p lanned use of the net proceeds from the IPO as described in our final prospectus for the IPO filed with the SEC pursuant to Rule 424(b ) under the Securities Act .
+Added: As of June 30, 2020, we used $4.0 million of the net proceeds from the IPO to fund the development of Haduvio for the treatment of pruritus associated with prurigo nodularis, the treatment of chronic cough in patients with IPF and general corporate purposes.
+Added: There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus for the IPO filed with the SEC pursuant to Rule 424(b) under the Securities Act .
We have invested the net proceeds from the IPO in money market funds.
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
−Removed: XBRL Taxonomy Extension Label Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: Filed herewith.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: TREVI THERAPEUTICS, INC.
−Removed: /s/ Christopher Seiter
−Removed: Christopher Seiter
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.